Amgen to Present at the UBS Global Life Sciences Conference

THOUSAND OAKS, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Wednesday, Sept. 22, 2010, at the Grand Hyatt in New York City, beginning at 9:00 a.m. Eastern Time.  Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.  

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

Justin Claeys, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.